



ophthalmology  
futures forums

Virtual2021

**ASIAN RETINA**

Thurs. 25 March



**Asian Retina Programme**  
*Virtual 2021*



# Imagine Your Happiness

Vision, a window to the world.  
With vision, we connect with others.  
With vision, we feel happiness.

That is why we at Santen believe  
seeing is integral to life.  
As a company focused on vision,  
we explore and grow the unlimited potential  
of our ability to see.  
Because we know we can one day  
achieve a world free of vision problems.  
Because we know we can one day  
create a future full of smiles  
where everyone's vision is nurtured.  
Until then, we will not stop challenging ourselves.

**Santen**

Imagine Your Happiness

# CONTENTS:

## RETINA PROGRAMME

<b>Welcome</b>	3
<b>Timings</b>	4
<b>Speakers</b>	
Presenting companies   Pannelists   Chairs	6
<b>Our sponsors</b>	7
Platinum	8
Gold	9
Silver	10
Bronze	11
New innovator	12
<b>Save the date 2021</b>	13
<b>Programme committee</b>	14





# WELCOME: RETINA VIRTUAL FORUM

Dear colleagues,

Welcome to the Ophthalmology Futures Asian Retina Forum 2021. The virtual format for this year's forum has presented us with challenges and opportunities. While missing the chance to network with participants in person, we are able to reach a much larger audience and include speakers who would otherwise not have been able to make the trip to Asia for an in person meeting.

The unique nature of innovation relating to diseases of the posterior segment led us to recognize the need for a standalone Retina Forum to increase our focus in this rapidly evolving space a few years ago and we have been delighted by the success of this format.

As in prior Retina Forums, we will have presentations from companies at various stages of the innovation process and panels on topics deemed to be of interest to all stakeholders. Ophthalmology Futures is dedicated to creating a novel program for each forum and this forum will, in particular, focus on issues deemed relevant to retina practice in Asia.

Highlights include sessions on: myopia, surgical robotics, imaging, telemedicine, gene therapy and real world pharmacologic treatment of posterior segment diseases. There will also be a region focused panel discussion on investment for diagnostic and therapeutic modalities aimed at reducing the burden of retinal diseases.

Ophthalmology Futures Forums would like to thank our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to have this meeting without a registration fee for all attendees!

Thank you for joining us!

Keith Barton and Kuldev Singh  
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.

Registered in England No: 8125858.



# TIMINGS:

## RETINA VIRTUAL FORUM

08:00 - 08:10

### WELCOME FROM THE CO-CHAIRS

Co-chairs

- Keith Barton
- Kuldev Singh

08:10 - 08:40

### PANEL 1: IS MYOPIA PREVENTION A VIABLE BUSINESS OPPORTUNITY?

Chair

- Marcus Ang

Panellists

- Kyoko Ohno Matsui
- Noel Brennan
- Olga Prenat
- Pei Chang Wu
- Reza Haque
- Seang Mei Saw
- Xiang Tian Zhou

08:40 - 09:30

### COMPANY PRESENTATIONS I

Companies

- AVECRIS Pte Ltd. | Volker Patzel
- GenSight Biologics | Magali Taiel
- Adverum Biotechnologies | Aaron Osborne
- Isarna Therapeutics | Marion Munk
- Iveric Bio | Pravin Dugel

09:30 - 10:00

### PANEL 2: REAL WORLD ANTI-VEGF UTILISATION IN ASIA AND THE OPPORTUNITY FOR GENE THERAPY

Co-chairs

- Adnan Tufail
- Timothy Lai

Panellists

- Abu Abraham
- Chris Brittain
- Dirk Sauer
- Gemmy Cheung
- Keith Lane
- Pravin Dugel
- Steve Pakola

10:00 - 10:40

### PANEL 3: INVESTMENT UPDATE & PANEL DISCUSSION

Chair

- Michael Keyoung

Panellists

- Ali Behbahani
- Amit Kakar
- Cynthia Bai
- Dennis Lam
- Malcolm Ngiam

10:40 - 11:30

### COMPANY PRESENTATIONS 2

- RE-VANA THERAPEUTICS | Michael O'Rourke
- AsclepiX Therapeutics, Inc. | Theresa Heah
- Ocuphire Pharma | Mina Sooch
- OcuTerra Therapeutics | Kerrie Brady

11:30 - 11:40

### SPONSOR SHOWCASE

11:40 - 12:10

### PANEL 4: ACCESS TO MODERN RETINA SURGERY IN ASIA: IS IT IMPROVING?

Chair

- Shu Yen Lee

Panellists

- Hai Lu
- Kazuaki Kadonosono
- Kim Ramasamy
- Paul Hallen
- Steve Charles
- Woohyok Chang

12:10 - 12:40

### PANEL 5: INNOVATION IN IMAGING AND TELEMEDICINE TO IMPROVE REMOTE ACCESS TO OPHTHALMIC CARE

Co-chairs

- Paisan Ruamviboonsuk
- Tien Yin Wong

Panellists

- Almira Chabi
- Joe Redner
- Kester Nahen
- Mingguang He
- Ryan Bouchard
- Xiaoyan Ding

12:40 - 13:30

### COMPANY PRESENTATIONS 3

- Notal Vision Inc. | Kester Nahen
- Risk Medical Solutions | Sigurbjörg Ásta Jónsdóttir
- NovaSight | Ran Yam
- Samsara Vision | Thomas Ruggia
- Norlase | Oliver Hvidt
- Preceyes | Marc De Smet

13:30 - 14:00

### PANEL 6: REDUCING THE UNMET NEED FOR CARE IN ASIA: SURGICAL ROBOTICS & SMART IMPLANTS

Chair

- Steve Charles

Panellists

- Luis Diaz-Santana
- Paul Hallen
- Vivek Dave
- Xiaorong Li

14:00 - 14:10

### SUMMARY

- Adnan Tufail

14:10 - 14:15


### CONCLUDING REMARKS FROM THE CO-CHAIRS

Co-chairs

- Keith Barton
- Kuldev Singh



## VISUAL FREEDOM IN ONE EXCEPTIONAL LENS



**Visian Toric ICL** provides outstanding refractive outcomes in patients with myopia and astigmatism<sup>1</sup>.

### The Visian Toric ICL clinical trial reported<sup>1</sup>:

- **98.4%** of patients would have the Visian Toric ICL procedure again
- Predictable outcomes realized across a broad range of treatment options
- **93.8%** of eyes maintained or gained 1 or more lines of BSCVA
- Rapid and stable achievement of outstanding MRSE and MRCyl
- In eyes with pre-op BSCVA 20/20 or better **100%** of eyes obtained **20/40** or better UCVA
- Over **94%** of eyes maintained rotational stability of **≤5°** at all post-op time points

1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014

# SPEAKERS: PRESENTING COMPANIES PANNELISTS & CHAIRS

## CHAIRS & PANELLISTS

### A

- **Abu Abraham**  
VP, Retina Therapeutic Area Strategy, Santen
- **Adnan Tufail**  
Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Trust, London, UK
- **Ali Behbahan**  
General Partner, New Enterprise Associates
- **Almira Chabi**  
VP, Glaucoma & Neuroprotection, Santen
- **Amit Kakar**  
Senior Partner, Head of Novo Holdings Asia

### C

- **Christopher Brittain**  
VP, Global Head of Ophthalmology Product Development, Genetech
- **Cynthia Bai**  
CMO, Rimongi Capital

### D

- **Dennis Lam**  
Director, C-MER International Eye Care Group
- **Dirk Sauer**  
Global Development Unit Head, Ophthalmology Unit, Novartis Pharma AG

### G

- **Gemmy Cheung Chui Ming**  
Consultant Ophthalmologist, Singapore National Eye Center

### J

- **Joe Redner**  
Head of ZEISS Australia & New Zealand, Head of APAC Sales/ Ophthalmic Devices, Medical Technology Business Group

### K

- **Kazuaki Kadonosono**  
Professor & Chair Yokohama City University, Japan
- **Keith Lane**  
Vice President, Posterior Segment department, Ora Clinical
- **Kester Nahen**  
CEO, Notal Vision Ltd.
- **Kim Ramasamy**  
CMO & Senior Retina Consultant, Aravind Eye Hospital, Madurai, India
- **Kyoko Ohno Matsui**  
Professor & Chairperson, Department of Ophthalmology & Visual Science, Tokyo Medical & Dental University, Japan

### L

- **Li Xiaorong**  
Director, Tianjin Medical University Eye Hospital School of Optometry & Eye Institute, China
- **Luis-Diaz Santana**  
Head of Ophthalmology, Cambridge Consultants

### M

- **Malcolm Ngiam**  
Deputy Managing Director, Essex Bio-Technology Ltd.
- **Marcus Ang**  
Senior Consultant Ophthalmologist, Cornea & Refractive Service, Singapore National Eye Center, Singapore
- **Michael Keyoung**  
Managing Director CBC Group (formerly C-Bridge Capital)
- **Mingguang He**  
Professor, The University of Melbourne, Australia

### N

- **Noel Brennan**  
Clinical Research Fellow, Myopia Control Platform, Johnson & Johnson Vision

### O

- **Olga Prenat**  
Global Director, Education & Professional Relations, Essilor International

### P

- **Paisan Ruamviboonsuk**  
Clinical Professor, Department of Ophthalmology, Rajavithi Hospital, Bangkok, Thailand
- **Paul Hallen**  
VP, Global Head Retina, Alcon
- **Pei Chang Wu**  
Professor & Director, Myopia Prevention & Treatment Center, Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
- **Pravin Dugel**  
Executive VP, Chief Business & Strategy Officer, Iveric Bio
- **Prof Hai Lu MD,**  
Vice Chair of Department of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, China

### R

- **Reza Haque**  
Senior VP & Global Head Ophthalmic Innovation Center, Santen
- **Ryan Bouchard**  
VP, Medical Devices, Ora, Inc.

### S

- **Seang Mei Saw**  
SERI Professor of Ophthalmology Research, Duke-NUS Medical School & Singapore Eye Research Institute
- **Shu Yen Lee**  
Senior Consultant & Head, Surgical Retina, Singapore National Eye Centre. Clinical Director, Retina Centre, Diabetes & Metabolism Centre, Singapore General Hospital, Singapore
- **Stephen Pakola**  
CMO, REGENXBIO Inc
- **Steve Charles**  
CEO & Founder, Charles Retina Institute & Clinical Professor of Ophthalmology, University of Tennessee, USA

### T

- **Tien Yin Wong**  
Arthur Lim Professor of Ophthalmology, Medical Director, Singapore National Eye Centre. Chairman, Singapore Eye Research Institute, Vice Dean, Duke-NUS Medical School, National University of Singapore
- **Timothy Lai**  
Clinical Professor (Honorary), Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, China

### V

- **Vivek Dave**  
Consultant Vitreo Retina, Smt. Kanuri Santhamma Centre for Vitreo Retinal diseases, LV Prasad Eye Institute, India

### W

- **Woohyok Chang**  
Doctor (M.D.), Founder & Owner, Chang's Retina Clinic

### X

- **Xiaoyan Ding**  
Director, Professor, Children's Center, Zhongshan Ophthalmic Center Sun Yet-sen University, China

### Z

- **Zhou Xiang Tian**  
Professor, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, China

## PRESENTING COMPANIES

### A

- **Adverum Biotechnologies**  
Aaron Osbourne, CMO
- **AsclepiX Therapeutics, Inc.**  
Theresa Heah, CMO
- **AVECRIS Pte Ltd.**  
Volker Patzel, Founder

### G

- **GenSight Biologics**  
Magali Taiel, CMO

### I

- **Isarna Therapeutics**  
Marion Munk, CEO
- **Iveric Bio**  
Pravin Dugel, CBO

### N

- **Norlase**  
Oliver Hvidt, CEO
- **Notal Vision Inc.**  
Kester Nahen, CEO
- **NovaSight**  
Ran Yam, CEO

### O

- **Ocuphire Pharma**  
Mina Sooch, CEO
- **OcuTerra Therapeutics**  
Kerrie Brady, CEO

### P

- **Preceyes**  
Marc De Smet, CMO

### R


- **RE-VANA THERAPEUTICS**  
Michael O'Rourke, CEO
- **Risk Medical Solutions**  
Sigurbjörg Ásta Jónsdóttir, CEO

### S

- **Samsara Vision**  
Thomas Ruggia, CEO

ALL OF THE SPEAKERS FOR THE ASIAN RETINA AND ASIAN FORUMS CAN BE FOUND ON OUR WEBSITE:

[OPHTHALMOLOGY-FUTURES.COM/FORUMS](https://ophthalmology-futures.com/forums)





# SPONSORS: ASIAN FORUMS 2021

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.

## PLATINUM

---



## GOLD

---



## SILVER

---



## BRONZE

---



## NEW INNOVATORS

---





# PLATINUM

## Alcon

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 70 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

For more information, please visit [www.alcon.com](http://www.alcon.com)

## Santen

As a global specialized company dedicated exclusively to ophthalmology, Santen brings 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide, Santen continues to grow its global presence across Asia, Europe, and North America, providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and infection to patients around the world.

For more information, please visit [www.santen.com](http://www.santen.com)



# GOLD



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL", which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: [www.discovericl.com](http://www.discovericl.com). Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

For more information, please visit the Company's website at [www.staar.com](http://www.staar.com)

## Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



### Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures Asian Retina Forum**

[www.zeiss.com](http://www.zeiss.com)

# SILVER

## ESSILOR

SEEING THE WORLD BETTER

Essilor International is the world's leading ophthalmic optics company. For 170 years the Essilor Group has put its expertise at the service of good vision in designing, manufacturing and distributing quality products and services to eyecare professionals but also via innovative business models. Essilor provides solutions to correct and protect the visual health of the 7.7 billion people in the world as part of its mission "improving lives by improving sight". A pioneer, innovation continuously drives Essilor growth, with more than €200 million each year dedicated to research and development. Essilor Group's flagship brands include Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant® and Bolon™. At Essilor we believe that people deserve the right vision solutions to unleash the full potential of their life, every day, all life long. That belief is anchored in the Group's mission.

For more information, please visit [www.essilor.com](http://www.essilor.com)



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

Please visit [www.regenxbio.com](http://www.regenxbio.com)



### Seeing beyond

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. With a special focus on ophthalmology and ophthalmic surgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

For more information, please visit [www.zeiss.com/meditec/int/about-us.html](http://www.zeiss.com/meditec/int/about-us.html)



# BRONZE



GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.

Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

Our second lead product candidate, GS030, combines gene therapy with optogenetics and is currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).

For more information, please visit [www.gensight-biologics.com](http://www.gensight-biologics.com)



Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

For more information on the Company, please visit [www.ivericbio.com](http://www.ivericbio.com)



**LENSAR**  
CATARACT LASER WITH AUGMENTED REALITY

LENSAR®, Inc., the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline® IV. This includes enhancements unique to LENSAR that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions.

Enhancements include IntelliAxis Refractive Capsulorhexis®, which incorporates lenticular markings to guide precise and confident toric IOL alignment, and wireless transfer of preoperative data from multiple devices, for seamless treatment planning. Iris registration further contributes to accuracy by automatically accounting for cyclotorsion. The LENSAR Laser is revolutionizing the surgeon's ability to deliver great outcomes for astigmatic patients.

Please visit [www.lensar.com](http://www.lensar.com)



Ora is the world's leading full-service ophthalmic research organization with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn 48 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's unique models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts to maximize the value of new product initiatives.

For more information, please visit [www.oraclinical.com](http://www.oraclinical.com)

# NEW INNOVATORS



LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.

For more information about the financing please contact Ramgopal Rao, CEO at [rrao@lensgen.com](mailto:rrao@lensgen.com) and visit [www.lensgen.com](http://www.lensgen.com)



Radiance Therapeutics is developing a next-generation beta therapy device for ophthalmic scar prophylaxis.

This therapeutic modality has been validated in 4 randomised controlled trials from preeminent ophthalmic research teams. Applied topically at the time of surgery, beta therapy has been shown to significantly improve glaucoma filtration surgery outcomes. The most recent of these studies reported odds ratios indicating that beta therapy patients were five and a half times more likely to experience lower IOP at the end of one year than patients treated with antimetabolite mitomycin-C.

For more information, please visit [www.radiancetherapeutics.com](http://www.radiancetherapeutics.com)



Re-Vana Therapeutics based in Northern Ireland and Tampa Florida, is a specialty ocular therapeutic and drug delivery company focused on the development of sustained release biologics and small molecules.

The Re-Vana platforms, which includes EyeLief® and OcuLief® photocrosslinked technologies, can deliver at least 6 months sustained delivery of large molecule biologics, including anti-VEGF therapies. Re-Vana's technology could also spur a new generation of small molecule therapeutics enabling up to 12 months delivery or greater.

For more information, please visit [www.revanatx.com](http://www.revanatx.com)



ophthalmology  
futures forums

Virtual2021

# SAVE THE DATES

**EURO VIRTUAL & HYBRID FORUMS**

**European Forum** *HYBRID 2021*

Thurs. 26 August

**Retina Forum** *Virtual 2021*

Thurs. 09 September

*(Forums begin @ 8am CET / GMT +1)*



[www.ophthalmology-futures.com](http://www.ophthalmology-futures.com)



# PROGRAMME COMMITTEE

**Ike Ahmed** | Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

**Jorge Alio** | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visum Corporation, Spain.

**Gerd Auffarth** | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

**Francesco Bandello** | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

**David Chang** | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

**Steve Charles** | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

**Paul Chew** | Professor of Ophthalmology, National University of Singapore, Singapore.

**Beatrice Cochener** | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

**Jost Jonas** | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

**Sir Peng Khaw** | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

**Shigeru Kinoshita** | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

**Richard Lindstrom** | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

**Boris Malyugin** | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

**Prof David Spalton** | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

**Prof Dr Ingeborg Stalmans** | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

**Paulo Eduardo Stanga** | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

**Paul Rosen** | Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Oxford, UK.

**José-Alain Sahel** | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments

of Ophthalmology, Quinze- Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Julian D. Stevens** | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

**Donald Tan Tiang Hwee** | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

**Marie-Jose Tassignon** | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

**Adnan Tufail** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

**Tien Yin Wong** | Vice Dean, Academic & Clinical Development, Duke-NUS Medical School, Singapore. Provost's Chair Professor, National University of Singapore. Deputy Group CEO (Research & Education), SingHealth, Singapore. Medical Director & Senior Consultant Ophthalmologist, Singapore National Eye Centre. Chair, Ophthalmology & Visual Sciences Academic Clinical Programme. Chairman, Board of Directors, Singapore Eye Research Institute, Singapore.

## ADVISORS

**Laurent Attias** | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

**Eugene de Juan** | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

**Tom Dunlap** | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

**Malvina Eydelman** | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

**Akira Kurokawa** | Chairman. Santen Pharmaceutical Co.

**James Mazzo** | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

**Naveed Siddiqi** | Novo Ventures.

## ORGANISING COMMITTEE

**Keith Barton** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK.

**Don Budenz** | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

**Lea Pietrolongo** | Operational Director, Ophthalmology Futures Forums, UK.

**Kuldev Singh** | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National





# We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at [alcon.com](https://alcon.com)

## CONNECT WITH US!



@AlconEyeCare  
@AlconCareers



@Alcon



@AlconLife

